novavax nuvaxovid - Search News

Order byBest matchMost fresh

Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

Top News

Overview

Impacts

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

The approval positions Novavax as the only non-mRNA COVID-19 vaccine with full FDA approval, offering a differentiated alternative amid growing mRNA fatigue.

· 2d

PharmExec · 3d

FDA Grants Full Approval to Novavax’s Nuvaxovid COVID-19 Vaccine

Stocktwits on MSN · 4d

Novavax Stock Rips Nearly 20% Pre-Market After FDA Approves Its COVID-19 Vaccine Nuvaxovid

FDA’s new approach to covid vaccines could have been way worse

Older adults can continue getting covid boosters, but not everyone who wants them can.

· 2d

MIT Technology Review · 13h

The FDA plans to limit access to covid vaccines. Here’s why that’s not all bad.

· 1d

FDA limits access to COVID-19 vaccine to older adults and other high-risk groups – a public health expert explains the new rules

US FDA Advisers to Weigh Composition of COVID Vaccines for 2025-2026

Public health experts say that there is no certainty on which strains are going to be dominant.

· 1d

FDA panel debates COVID vaccine recipe as questions swirl about fall shots

· 1d

COVID shots should target newer strains of JN.1 variant in 2025-26 campaign, US FDA advisers say

Yahoo Finance2d

Novavax, Inc. (NVAX)

Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Nuvaxovid™ for active immunization to ...

2don MSN

BofA Reiterates Hold Rating on Novavax (NVAX) Stock

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from Sanofi during Q3 and an additional $50 million in the second half of